CA2651557A1 - 17-oxymacbecin derivatives and their use in the treatment of cancer and/or b-cell malignancies - Google Patents

17-oxymacbecin derivatives and their use in the treatment of cancer and/or b-cell malignancies Download PDF

Info

Publication number
CA2651557A1
CA2651557A1 CA002651557A CA2651557A CA2651557A1 CA 2651557 A1 CA2651557 A1 CA 2651557A1 CA 002651557 A CA002651557 A CA 002651557A CA 2651557 A CA2651557 A CA 2651557A CA 2651557 A1 CA2651557 A1 CA 2651557A1
Authority
CA
Canada
Prior art keywords
oxymacbecin
analogue
post
macbecin
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002651557A
Other languages
English (en)
French (fr)
Inventor
Christine Martin
Ming Zhang
Sabine Gaisser
Nigel Coates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotica Technology Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2651557A1 publication Critical patent/CA2651557A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
CA002651557A 2006-05-09 2007-05-09 17-oxymacbecin derivatives and their use in the treatment of cancer and/or b-cell malignancies Abandoned CA2651557A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0609117.7A GB0609117D0 (en) 2006-05-09 2006-05-09 Novel compounds
GB0609117.7 2006-05-09
PCT/EP2007/054473 WO2007128827A1 (en) 2006-05-09 2007-05-09 17-oxymacbecin derivatives and their use in the treatment of cancer and/or b-cell malignancies

Publications (1)

Publication Number Publication Date
CA2651557A1 true CA2651557A1 (en) 2007-11-15

Family

ID=36637122

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002651557A Abandoned CA2651557A1 (en) 2006-05-09 2007-05-09 17-oxymacbecin derivatives and their use in the treatment of cancer and/or b-cell malignancies

Country Status (11)

Country Link
US (1) US20100068203A1 (cg-RX-API-DMAC10.html)
EP (1) EP1940798A1 (cg-RX-API-DMAC10.html)
JP (1) JP2009536934A (cg-RX-API-DMAC10.html)
KR (1) KR20090005377A (cg-RX-API-DMAC10.html)
CN (1) CN101437802A (cg-RX-API-DMAC10.html)
AU (1) AU2007247119A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0711092A2 (cg-RX-API-DMAC10.html)
CA (1) CA2651557A1 (cg-RX-API-DMAC10.html)
GB (1) GB0609117D0 (cg-RX-API-DMAC10.html)
MX (1) MX2008014279A (cg-RX-API-DMAC10.html)
WO (1) WO2007128827A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0718562A2 (pt) * 2006-11-09 2014-04-08 Biotica Tech Ltd Composto, processo para preparar e para gerar análogo de macbecina, análogo de macbecina, composição farmacêutica, uso do análogo de macbecina, e, cepa engenheirada.
US9967590B2 (en) 2008-04-10 2018-05-08 Qualcomm Incorporated Rate-distortion defined interpolation for video coding based on fixed filter or adaptive filter
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
CN110999828A (zh) * 2019-12-19 2020-04-14 上海海洋大学 改变鱼类体色分布模式的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5360694A (en) * 1992-10-14 1994-05-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Tumoricidal activity of benzoquinonoid ansamycins against prostate cancer and primitive neural malignancies
JPH11504924A (ja) * 1995-05-02 1999-05-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ベンゾキノン類アンサマイシンによる熱耐性の誘導

Also Published As

Publication number Publication date
MX2008014279A (es) 2008-11-26
GB0609117D0 (en) 2006-06-21
JP2009536934A (ja) 2009-10-22
WO2007128827A1 (en) 2007-11-15
US20100068203A1 (en) 2010-03-18
EP1940798A1 (en) 2008-07-09
CN101437802A (zh) 2009-05-20
WO2007128827A8 (en) 2008-01-03
BRPI0711092A2 (pt) 2011-08-23
AU2007247119A1 (en) 2007-11-15
KR20090005377A (ko) 2009-01-13

Similar Documents

Publication Publication Date Title
US20090209494A1 (en) 21-deoxymacbecin analogues useful as antitumor agents
US20090253667A1 (en) 18 ,21-Didesoxymacbecin Derivatives for the Treatment of Cancer
US20100068203A1 (en) 17-Oxymacbecin Derivatives and Their Use in the Treatment of Cancer and/or B-Cell Malignancies
US20110160175A1 (en) 18,21-Didesoxymacbecin Derivatives for the Treatment of Cancer
EP1973883B1 (en) Novel compounds and methods for their production
US20090117127A1 (en) Novel Compounds and Methods for Their Production
US20090209507A1 (en) 15-O-Desmethylmacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies
US20110091452A1 (en) 4,5-Dihydromacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies
US20090298804A1 (en) Novel Compounds and Methods for Their Production
CA2679224A1 (en) Novel compounds
EP2079700A1 (en) 18, 21-didesoxymacbecin derivatives for the treatment of cancer

Legal Events

Date Code Title Description
FZDE Discontinued